Pharm. D Profile picture
23 Feb, 5 tweets, 1 min read
$PAVM Updates from Earnings call
1) Major Esoguard commercial by Lucid to assure sufficient testing capacity and geographic coverage to accommodate demand
2) Spinoff Lucid into a separate public company, either through an IPO or a business combination with a healthcare SPAC
$PAVM
3) Spinoff: access to growth capital and other resources necessary to execute and PAVmed will remain Lucid’s largest shareholder following any spin-off transaction. PAVmed owns 82% of Lucid’s outstanding common stock. 4) Full grown sales team for Esoguard commercialization
$PAVM
5) So far trained clinicians at approximately 150 accounts and actively engaged with 100s more.
6) "Gastroenterologists have responded very positively to EsoGuard because it helps them expand their funnel of new esophageal disease patients."
$PAVM
7) Lucid will retain and train a network of full-time nurses. Each nurse could be either in exam rooms leased from a partner physician, in EsoGuard testing centers and national laboratory testing companies, as well as national pharmacy companies with mini clinics.
$PAVM
8) PAVmed has Stan Lapidus (Former CEO of $EXAS, $23B MARKET CAP) invaluable resource for PAVM
9) CarpX European approval next QTR likely
10) Early 2022 to submit the PMA and hopefully secure IVD registration for Esoguard

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Pharm. D

Pharm. D Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Pharmdca

16 Feb
$MREO Thread
1)Focus of this thread: Etigilimab and Alvelestat

Financials: Roughly $200 million in cash (50M from upfront payment from Ultragenyx & $115M raise from a strong secondary last week). Company fully funded into 2023
Disclaimer: I own a significant position LT
$MREO
2) Outstanding shares: 67 plus million shares
Market cap: ~$345 million

Recent position by Orbimed stake at 9.9% of the company. and recently Ikarain added to MREO position.
Merck, Roche, Arcus, Beigene all moving into anti-TIGIT drug development
$MREO
3) Strong interest in Anti-TIGIT approaches in oncology. Why TIGIT Target: TIGIT and PD-1 has been shown to be over expressed on tumor antigen-specific cells. Now inhibiting TIGIT can enhance anti tumor T cell responses.
Read 7 tweets
12 Feb
$DMTK Target $150 plus LT Why I'm so bullish and continue to add shares even at such high prices. Potential skin cancer market opportunity $10 Billion plus. The First Non-invasive Gene Expression and Mutation Test to
Enhance Melanoma Detection avoiding unnecessary surgeries.
$DMTK is a leader in precision dermatology
enabled by a non-invasive skin genomics platform. KEY WORD: NON INVASIVE vs SURGICAL BIOPSIES. Fantastic results announced from its TRUST Study of the company’s non-invasive melanoma rule-out test, the Pigmented Lesion Assay (PLA).
$DMTK
"Of the 1,781 lesions in the long-term follow-up cohort, there were no melanoma deaths or late-stage melanoma diagnoses reported in the full cohort.
10 lesions had received a melanoma diagnosis after initial testing, with four at Stage 0 (in situ) and six at Stage 1a."
Read 6 tweets
7 Feb
$DCTH Getting closer to an imminent catalyst
1) Company set to report PH 3 results for Chemostat in Liver dominant Metastatic Ocular Melanoma
2) Currently no treatment for this ultra orphan indication.
3) In 2013, FDA issued CRL and requested company to conduct another trial
$DCTH
4) WHY CRL in 2013: The overall response rate (ORR) was 27.3% for Chemosat group, VS 4.1% in control group and PFS was 7 months for Chemosat group VS 1.6 months for control group
5) If EFFICACY was much better than the placebo as I pointed, why company received a CRL
$DCTH
6) CRL: Over 90% patients suffered grade 3-4 adverse events
7) 4 Treatment related Deaths in the PH 3 Trial
8) So now what????
9) Company ran another PH3 trial with a new improved protocol to enhance safety that was the reason company was issued a CRL despite efficacy
Read 6 tweets
26 Jan
$MYOV THREAD 1
Prostate Cancer: Relugolix PH3 HERO study of once-daily Oral relugolix 120mg- Met primary endpoints and met all six key secondary endpoints in men with advanced prostate cancer. 96.7% of men who received oral relugoix achieved sustained testosterone suppression.
$MYOV 2
Collaboration with Pfizer for jointly developing and commercializing relugolix in advanced prostate cancer. MYOV will receive up to $4.2B including an upfront payment of $650M, $200M in potential regulatory milestones and tiered sales milestones.
$MYOV 3
PFE’s role in launching the drug which is huge since most new drug launches falters initially with lack of financial resources and marketing strategies. PFE collaboration creates significant value for MYOV through Accelerated uptake, Higher Revenue Peak, Shared Expenses
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!